Hepatocellular Cancer Clinical Trial
Official title:
Correlation of Necrosis With DC Bead LUMI (TM) Distribution
The primary purpose of the study is to evaluate the distribution of radiopaque microspheres loaded with doxorubicin in the treatment of unresectable HCC. Prospective, single arm, open label, single centre, pilot study. All patients will undergo clinical follow-up. Twenty patients will be enrolled.
The primary purpose of the study is to evaluate the distribution of radiopaque microspheres loaded with doxorubicin in the treatment of unresectable HCC. Prospective, single arm, open label, single centre, pilot study. All patients will undergo clinical follow-up. Twenty patients will be enrolled. Primary endpoint : Local response (evaluated with CT and MRI at 4 to 6 weeks post each procedure and at 6 months according to mRECIST) in patients with intermediate-stage HCC following chemoembolisation with radiopaque bead. Secondary endpoints include: 1) Better definition of end point of embolization for drug eluting beads : Ability to achieve near-stasis during chemoembolisation procedure in the tumour feeding vessels using intra-procedural imaging feedback from the radiopaque bead (early visualization of non target embolization 2) Total dose needed for tumor devascularization 3)Distribution of radiopaque beads and correlation with necrosis and adverse events ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03971201 -
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
|
Phase 2 | |
| Recruiting |
NCT05489250 -
The PLATON Network
|
||
| Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
| Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
| Terminated |
NCT00878215 -
Clinical Application of Image-Guided Liver Surgery
|
Phase 2 | |
| Completed |
NCT04212286 -
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
|
N/A | |
| Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
| Completed |
NCT02073435 -
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
|
||
| Active, not recruiting |
NCT01522937 -
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
|
Phase 2 | |
| Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04166240 -
Measuring and Improving the Safety of Test Result Follow-Up
|
N/A | |
| Withdrawn |
NCT02288507 -
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
|
Phase 1 | |
| Terminated |
NCT03026803 -
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Recruiting |
NCT05100082 -
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
|
||
| Active, not recruiting |
NCT03195699 -
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT02616692 -
HCC Patient Preferences in Japan
|
N/A | |
| Active, not recruiting |
NCT03132792 -
AFPᶜ³³²T in Advanced HCC
|
Phase 1 | |
| Not yet recruiting |
NCT06239194 -
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01849588 -
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
|
Phase 4 |